Global Tissue Engineering Technologies, Markets, Forecasts Report 2018-2028: Market Products to Exceed $4.8 Billion

Dublin, Dec. 13, 2017 (GLOBE NEWSWIRE) -- The "Tissue Engineering 2018-2028: Technologies, Markets, Forecasts" report has been added to Research and Markets' offering.

A market forecast for tissue engineered products is provided for the years 2018 - 2028, where the total value for tissue engineered products is predicted to surpass $4.8 billion. This market is broken down into key applications of therapies (clinical use) and tissue models (research use). Key players in both applications are presented, and the value chain and relevant business models are discussed.

Applications

The biggest applications for engineered tissues are in research and development, and in medicine. This report discusses the following key applications of tissue engineering:

• Testing of cosmetics and other consumer goods
• Drug screening
• Personalized medicine
• Regenerative medicine
• Cell-based biosensors
• Food and other animal products
• Aesthetics

Clinical Landscape

A chapter of this report is dedicated to the use of tissue engineering products in medicine. The following classes of tissue engineered therapies are highlighted:

• Tissue engineered therapies with FDA marketing approval
• Tissue engineered therapies close to IND submission
• Competitive landscape of tissue engineered skin
• Competitive landscape of tissue engineered cartilage

Additionally, a summary of ongoing clinical trials of tissue engineered products is provided, organized by trial phase, tissue type, and sponsor.

The rest of this chapter describes and discusses the dynamics of US and EU markets, with a look at relevant regulatory pathways, exemptions, and loopholes for tissue engineered products, as well as speculations on the future of regulating this novel class of therapy.

Technology

A wide range of approaches are still being explored in tissue engineering, and this report covers both the most innovative and cutting-edge techniques as well as more established technologies.

Technologies presented in this report are:

• Semi-permeable membranes
• Cell-laden hydrogels
• 3D bioprinting
• 3D printing (including thermoplastic extrusion, material jetting, stereolithography, selective laser sintering)
• Decelluarization and recellularization of organs
• Phase separation, freeze-drying, solvent casting and particle leaching, gas foaming
• Electrospinning and melt electrospinning
• Self-assembly and self-organization.

Key Topics Covered:

1. EXECUTIVE SUMMARY
1.1. Overview
1.2. What is Tissue Engineering?
1.3. Key Players
1.4. Key Drivers
1.5. Key Opportunities
1.6. Tissue Engineered Products Market Forecast 2018 - 2028
1.7. Tissue Engineered Products for Clinical Use Market Forecast 2018 - 2028
1.8. Tissue Engineered Products for Research Use Market Forecast 2018 - 2028
1.9. Key Technologies
1.10. Key Challenges

2. INTRODUCTION
2.1. Report Scope
2.2. Advantages of 3D Cell Culture
2.3. Key Driver: Regenerative Medicine
2.4. Key Driver: Unmet Need in Organs for Transplant
2.5. Key Driver: Product Testing in Medicine
2.6. Key Driver: Avoiding Costly Drug Trial Failures
2.7. Key Driver: Product Testing in Consumer Products
2.8. Current Challenges: Biological
2.9. Current Challenges: Commercialization
2.10. Tissue Engineering in 2017

3. KEY OPPORTUNITIES
3.1. Overview
3.2. Testing of Cosmetics and Other Consumer Goods
3.3. Drug Screening
3.4. Drug Screening: Drug Development Process
3.5. Drug Screening: Benefits of Tissue Engineering
3.6. Drug Screening: Cancer
3.7. Drug Screening: Organ-on-a-chip
3.8. Personalised Medicine
3.9. Cell-Based Biosensors
3.10. Food and Other Animal Products
3.11. Esthetics

4. TISSUE ENGINEERING CLINICAL LANDSCAPE
4.1. Overview
4.2. Regenerative Medicine
4.3. Competing Products
4.4. Competing Products: Advantages and Disadvantages
4.5. Commercial Activity
4.6. The US Market
4.7. Products with FDA Marketing Approval
4.8. The European Market
4.9. Clinical Trials
4.10. Clinical Trials: By Indication and Phase
4.11. Skin: Clinical Products
4.12. Cartilage: Clinical Products
4.13. Pre-Clinical Products
4.14. Regulatory Exemptions
4.15. Hospital Exemption Scheme
4.16. Hospital Exemption Scheme: Problems
4.17. 21st Century Cures Act and the Regenerative Medicine Advanced Therapy Designation
4.18. Orphan Drug Designation
4.19. Scams and Unauthorized Treatments
4.20. Moving to Conditional Approval
4.21. Moving to Conditional Approval: Case Study
4.22. Learning from Medical Innovations
4.23. Future

5. MARKETS AND FORECASTS
5.1. Overview
5.2. Market Barriers
5.3. Tissue Engineering Value Chain
5.4. Tissue Engineering Value Chain: Discussion
5.5. Forecasts
5.6. Tissue Engineered Products Market Forecast 2018 - 2028
5.7. Companies with Marketed Clinical Products
5.8. Companies Developing Engineered Tissues for Clinical Use
5.9. Business Models: Engineered Autologous Tissues
5.10. Business Models: Cryopreserved Allogeneic Tissues
5.11. Tissue Engineered Products for Clinical Use Market Forecast 2018 - 2028
5.12. Companies Engineering Tissues for Research Use
5.13. Business Models: Tissues for Research Use
5.14. Tissue Engineered Products for Research Use Market Forecast 2018 - 2028
5.15. Companies Producing Organ-On-A-Chips
5.16. Companies Producing Lab-Grown Meat
5.17. Scaffold Manufacturers
5.18. 3D Bioprinter Market and Forecasts
5.19. Growing 3D Bioprinting Market
5.20. 3D Bioprinting Value Chain
5.21. 3D Bioprinting Value Chain: Discussion
5.22. 3D Bioprinters by Cost and Technology
5.23. 3D Bioprinter Market Forecast 2018 - 2028
5.24. Caveats

6. TISSUE ENGINEERING TECHNOLOGIES
6.1. Overview

7. ESTABLISHED TECHNOLOGIES
7.1. Introduction
7.2. Semi-Permeable Membranes
7.3. Key Semi-Permeable Membrane Manufacturers
7.4. Hydrogels
7.5. Cell-Laden Hydrogels
7.6. Cell-Laden Hydrogels: Companies
7.7. Cell-Laden Hydrogels: SWOT Analysis

8. 3D BIOPRINTING
8.1. Introduction
8.2. 3D Bioprinting Process
8.3. Comparison of Key Specifications
8.4. 3D Bioprinting Technology Comparison
8.5. Inkjet: Thermal
8.6. Inkjet: Piezoelectric
8.7. Inkjet: Companies
8.8. Inkjet: SWOT Analysis
8.9. Extrusion: Pneumatic
8.10. Extrusion: Mechanical
8.11. Extrusion: Companies
8.12. Extrusion: Example
8.13. Extrusion: SWOT Analysis
8.14. LIFT: Laser-Induced Forward Transfer
8.15. LIFT: Companies
8.16. LIFT: SWOT Analysis
8.17. Microvalve: Solenoid
8.18. Microvalve: Companies
8.19. Microvalve: SWOT Analysis
8.20. Industry-wide Technical Challenges
8.21. The Ideal 3D Bioprinter
8.22. Animal Studies
8.23. Future Technological Directions

9. SCAFFOLD TECHNOLOGIES
9.1. Tissue Engineering Scaffolds
9.2. Ideal Scaffold

10. 3D PRINTING
10.1. Introduction
10.2. Examples of 3D Printed Medical Products
10.3. Thermoplastic Extrusion
10.4. Thermoplastic Extrusion: Example
10.5. Thermoplastic Extrusion: Key Manufacturers
10.6. Thermoplastic Extrusion: SWOT Analysis
10.7. Material Jetting
10.8. Material Jetting: Key Players
10.9. Material Jetting: SWOT Analysis
10.10. Stereolithography
10.11. Stereolithography: Key Players
10.12. Stereolithography: SWOT Analysis
10.13. Stereolithography: Microstereolithography
10.14. Stereolithography: Projection
10.15. Stereolithography: Multiphoton Lithography
10.16. Stereolithography: Multiphoton Lithography: Example
10.17. Selective Laser Sintering
10.18. Selective Laser Sintering: Key Players
10.19. Selective Laser Sintering: SWOT Analysis

11. DECELLULARIZED ORGANS
11.1. Introduction
11.2. History
11.3. Decellularization
11.4. Recellularization
11.5. Companies
11.6. Future Technological Directions
11.7. Bioreactors

12. OTHER SCAFFOLD TECHNOLOGIES
12.1. Introduction
12.2. Phase Separation
12.3. Freeze-Drying
12.4. Freeze-Drying: Companies
12.5. Solvent Casting and Particle Leaching
12.6. Gas Foaming
12.7. Chemical Processes: Strengths and Weaknesses
12.8. Textile Technologies
12.9. Electrospinning
12.10. Cell Electrospinning
12.11. Electrospinning: Examples
12.12. Electrospinning: SWOT Analysis
12.13. Melt Electrospinning
12.14. Melt Electrospinning: SWOT Analysis
12.15. Electrospinning: Companies

13. SCAFFOLDLESS TECHNOLOGIES
13.1. Introduction
13.2. Cell Spheroids
13.3. Cell Spheroids: Self-Assembly
13.4. Cell Spheroids: Self-Organization
13.5. Cell Spheroids: Rotational Culture Equipment
13.6. Cell Spheroids: Key Companies
13.7. Cell Sheets
13.8. Cell Therapy Devices
13.9. Cell Therapy Devices: Companies

14. TISSUE ENGINEERING CHALLENGES
14.1. Industry-Wide Technical Challenges
14.2. Biopreservation
14.3. Vascularization

For more information about this report visit https://www.researchandmarkets.com/research/zz6x7g/global_tissue?w=12

                    
                    
                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             Related Topics: Biomaterials